Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269788 | 0.80 | BCAT2 (0.60) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL5136561 | 0.74 | ALDH1A1 (0.58) | HTTALDH1A1TDP1MAPTLMNA | |
| SCHEMBL29975518 | 0.73 | ALDH1A1 (0.56) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL1780458 | 0.73 | ALDH1A1 (0.56) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL11803328 | 0.73 | HTT (0.59) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL20115779 | 0.71 | PI4KA (0.44) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL9356766 | 0.71 | ALDH1A1 (0.54) | BCAT2HTTALDH1A1TDP1MAPT | |
| SCHEMBL10483749 | 0.70 | ALDH1A1 (1.00) | HTTALDH1A1TDP1MAPTLMNA | |
| SCHEMBL1520395 | 0.70 | MAPT (0.63) | HTTALDH1A1TDP1MAPTLMNA | |
| SCHEMBL15881921 | 0.69 | HTT (0.59) | HTTALDH1A1TDP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| EP-1871345-B1 | NANOPARTICULATE ERLOTINIB FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2012-08-01 | — | — | EP | disclosed |
| EP-1871345-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | Elan Pharma International Limited (IE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | ELAN PHARMA INTERNATIONAL, LIMITED | 2006-11-02 | — | — | US | disclosed |
| WO-2006110811-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | KRAS, NRAS, ABL1 | BCAT2 1675/4885HTT 619/4885ALDH1A1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.